House Status:
Senate Status:
Senate Status:
Minutes for HB2218 - Committee on Health and Human Services
Short Title
Amending the definition of "psilocybin" in the uniform controlled substances act to exclude the pharmaceutical composition of crystalline polymorph psilocybin and adding crystalline polymorph psilocybin to schedule IV of the uniformed controlled substance act.
Minutes Content for Tue, Feb 11, 2025
Carly Choi, Revisor of Statutes, provided an overview of HB2218.
Tess Bettler, Senior Manager, Advocacy and State Government Policy, Compass Pathways, provided testimony in support of HB2218 (Attachment 2). The bill would move a pharmaceutical composition of crystalline polymorph psilocybin once approved by the Food and Drug Administration from Schedule I to Schedule IV in the Kansas Controlled Substance Act. Psilocybin is currently a Schedule I drug both federally and in Kansas. Currently pharmaceutical grade formulations of synthesized psilocybin are being studied for treatment of serious and difficult to treat mental health conditions. In the event that a composition of crystalline polymorph psilocybin is approved by the FDA, the DEA will be expected to make a rescheduling decision soon after approval. Kansas law does not automatically follow DEA rescheduling decisions. HB2218 would allow for expedited access to new treatments by moving crystalline polymorph psilocybin to Schedule IV.
Ms. Bettler responded to questions from the committee.
Written only testimony in opposition was provided by the following:
James Davis, Private Citizen (Attachment 3)
Written only neutral testimony was provided by the following:
Alexandra Blasi, Executive director, Kansas Board of Pharmacy (Attachment 4)
